Singapore markets open in 3 hours 45 minutes

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.36+0.20 (+3.88%)
At close: 04:00PM EST
5.42 +0.06 (+1.12%)
After hours: 04:09PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.16
Open5.20
Bid5.32 x 800
Ask5.34 x 3200
Day's range5.04 - 5.42
52-week range1.01 - 5.55
Volume193,919
Avg. volume296,340
Market cap218.209M
Beta (5Y monthly)2.59
PE ratio (TTM)N/A
EPS (TTM)-1.48
Earnings date14 Mar 2024 - 18 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.57
  • Business Wire

    Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

    SOUTH SAN FRANCISCO, Calif., January 30, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.

  • Business Wire

    Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

    SOUTH SAN FRANCISCO, Calif., January 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).

  • Business Wire

    Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

    SOUTH SAN FRANCISCO, Calif., January 05, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).